Biopharmaceutical company developing innovative therapies for cardiorenal diseases.
Ardelyx, Inc., a dynamic biopharmaceutical firm, focuses on discovering, developing, and commercializing innovative medicines aimed at addressing gastrointestinal and cardiorenal diseases globally. Founded in 2007 and based in Waltham, Massachusetts, the company is dedicated to advancing treatments that improve patient outcomes in critical therapeutic areas.
Central to Ardelyx's portfolio is tenapanor, its leading product candidate. Currently in Phase III clinical trials, tenapanor targets irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease patients on dialysis. Additionally, Ardelyx is developing RDX013, designed as a potassium secretagogue to manage hyperkalemia prevalent among patients with kidney and heart diseases. The company also explores RDX020, an early-stage program addressing metabolic acidosis, a significant electrolyte disorder in chronic kidney disease patients.
Ardelyx has established strategic partnerships with leading pharmaceutical companies including Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada. These collaborations enhance the development and commercialization efforts of tenapanor across diverse international markets.
With a steadfast commitment to scientific innovation and clinical excellence, Ardelyx continues to expand its impact in the biopharmaceutical industry. By leveraging its deep expertise and collaborative partnerships, the company aims to bring transformative therapies to patients worldwide, addressing critical unmet medical needs in gastrointestinal and cardiorenal dizorders.